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Abstract
Background: Occult invasive cervical cancer (OICC) is sometimes incidentally found in surgical specimens after a
simple hysterectomy (SH). This study was aimed at identifying a subset of patients with OICC who have a favorable
prognosis. This patient group may not require adjuvant radiotherapy and other procedures.
Methods: The medical records of women in whom OICC was detected after an inadvertent SH were retrospectively
reviewed. The relevant data, including clinicopathological characteristics, treatment and clinical outcome were
evaluated. The primary and secondary endpoints were overall survival (OS) and relapse-free survival (RFS), respectively.
Results: Eighty-nine patients who met the inclusion criteria were included for analysis, and the risk of OICC was found to
be 1.9 %. Finding an invasive cancer in a hysterectomy specimen after a conization procedure that shows positive
margins was the most common reason (41.6 %) for the performance of inadvertent SH. In the univariate analysis, a tumor
width > 20 mm, deep stromal invasion, and lymph node metastasis (LNM) were adversely associated with relapse (P < 0.
001, < 0.001, and = 0.001, respectively) and survival (P = 0.003, 0.004, and 0.027, respectively), although these parameters
were not independently associated with patient prognoses in the multivariate analysis. In patients with a tumor width≤
20 mm and superficial stromal invasion in the observation subgroup, the 5-year RFS and 5-year OS were both 100 %,
whereas they were 57.1 % and 66.7 %, respectively, in patients with a tumor size > 20 mm and deep stromal invasion in
the radiotherapy or chemotherapy subgroup (P < 0.001, and = 0.008, respectively).
Conclusions: Simple observation after a lymphadenectomy procedure may be feasible in OICC patients with a tumor
width≤ 20 mm, superficial stromal invasion, a negative section margin in hysterectomy specimens, and no LNM.
Keywords: Cervical cancer, Inadvertent hysterectomy, OICC, Adjuvant treatment, Simple observation
Background
The optimal treatment for invasive cervical cancer con-
sists of either a radical hysterectomyand pelvic lymphade-
nectomy or radiotherapy (RT). Comparable rates of
survival are obtained when regimens are initiated in early
stage disease, regardless of which therapeutic modality is
utilized [1]. However, occult invasive cervical cancer
(OICC) is sometimes incidentally found in surgical speci-
mens after a simple hysterectomy (SH). SHs are per-
formed for supposedly benign gynecologic conditions and
pre-invasive cervical lesions or microinvasive cervical can-
cer. For lesions that do not qualify as microinvasive, the
SH procedure is suboptimal and significantly associated
with inferior survival rates [2, 3]. Further treatment, such
as RT [4–12] or radical parametrectomy (RP) [13–21], is
therefore warranted in these patients. However, a growing
number of retrospective studies [22–27], in addition to
one of our previously published studies [28], have
suggested that RP can be safely omitted in patients with
small volume tumors (a largest tumor diameter ≤ 2 cm)
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and other favorable pathological characteristics, such as
superficial stromal invasion (≤10 mm or 5 mm), and nega-
tive lymphovascular space involvement (LVSI). All of these
selection criteria can be reliably evaluated using SH speci-
mens. Thus, the aim of the present study is to identify a
subset of patients with OICC following inadvertent SH
who experienced a favorable outcome. This patient group
may not require adjuvant RT or other procedures.
Methods
The medical records of women with an invasive cervical
cancer that was detected after inadvertent SH who were
treated at one of 4 hospitals from October 2003 to February
2012 were reviewed. The hospitals included The Peking
Union Medical College Hospital, Affiliated Hospital of
Medical College Qingdao University, The Second Hospital
of Hebei Medical University, and Beijing Chao-Yang
Hospital, Capital Medical University. Demographic and
clinico-pathological data were retrospectively reviewed.
Two independent pathologists with extensive backgrounds
in gynecologic pathology reviewed all of the pathological
slides for the specific purposes of this study and were
blinded to patient outcomes. During this review, we col-
lected all missing data on pathologic risk factors.
Tumor width, which was defined as the longest tumor
diameter, was evaluated using a postoperative gross meas-
urement before the tissue was fixed. Based on these data,
the tumors were divided according to size as either ≤ 2 cm
or > 2 cm. Stromal invasion depth was measured perpen-
dicularly from the basement membrane of the surface epi-
thelium using an ocular micrometer. The degree of stromal
invasion was classified as either deep or superficial based
on its depth (>5 mm or ≤ 5 mm, respectively). If there was
substantial residual tumor in an RH specimen after a previ-
ously performed conization, the longest diameter was
determined to be the sum of the tumor width of the cone
biopsy plus that of the RH specimen obtained from the
conization site. Similarly, the maximum depth of invasion
was determined as the sum of the invasion depth observed
in the cone biopsy and that observed in the RH specimen
obtained from the conization site. LVSI was defined as the
unequivocal presence of malignant cells in endothelial-lined
spaces as observed upon a histological examination of the
specimen. Marginal status was interpreted as positive when
an invasive carcinoma or an in situ carcinoma was found in
a parametria or vagina of a hysterectomy specimen. Patients
with microinvasive disease (stromal invasion depth ≤ 3 mm)
and no LVSI were excluded from the analyses because SH
alone is the definitive treatment for this group and is not
associated with any safety concerns [29, 30].
Adjuvant treatment after SH included pelvic lymphade-
nectomy with or without para-aortic lymphadenectomy
and RT or concurrent chemoradiotherapy (CCRT). RT was
administered in patientswith at least 1 high-risk
pathological factor, such as vaginal invasion, parametrial
invasion, or lymph node metastasis (LNM), and patients
with 2 intermediate-risk factors for relapse, including LVSI,
deep stromal invasion or microscopic metastasis in > 2
lymph nodes [31, 32]. The RT treatment consisted of whole
pelvic RT with a total dose of 45 Gy that was divided into
20–30 applications. For CCRT patients, cisplatin (40 mg/
m2) was administered weekly. For patients who failed to
meet the above criteria, the decision to administer RT was
generally based on the patient’s age, their informed consent,
and the doctor’s recommendation.
After the completion of treatment, the women were
followed up every 3 months during the first year, every
4 months during the second year and every 6 months
thereafter. A ThinPrep cytologic test was performed every
6 months. In women for whom regular follow-up informa-
tion was not available, an effort was made to contact these
patients by telephone or correspondence to obtain this
information. Relapse was defined by clinical or imaging
evidence and was confirmed pathologically. Local recur-
rence (LR) was defined as recurrence in the pelvis, and
relapse-free survival (RFS) was defined as a lack of LR and
distant metastasis. RFS times were calculated as the period
between the date of the initial surgery and the date of
relapse. Women who were disease-free at the time of their
last visit were censored. Overall survival (OS) times were
calculated in months from the date of the initial surgery to
the date of patient death from the disease. Patients who
died of other conditions or had survived at the time of their
last visit were censored.
All statistical analyses were performed using SAS® Ver-
sion 9.2 (SAS Institute, Cary, NC). All tests were 2-sided,
and P-values ≤ 0.05 were considered statistically significant.
The frequency distributions of clinicopathological parame-
ters were compared between groups using Chi-square or
Fisher’s exact tests, and a Kruskal-Wallis test was used to
compare mean values. The Kaplan-Meier method was used
to analyze relapse and survival times. A log rank test was
used to compare different survival curves. A Cox propor-
tional hazards model was applied to all of the parameters
that were found to be significant in the univariate analysis.
Results
During the study period, 4635 consecutive patients with
cervical cancer were treated at the four hospitals. One
hundred and twenty-eight women were diagnosed with
cervical cancer after inadvertent SH. Thirty-one of these
patients had microinvasive disease (stromal invasion
depth ≤ 3 mm) but were negative for LVSI and were
therefore excluded. Eight patients without complete
medical records or follow-up information were also
excluded. Consequently, 89 (1.9 %) women were eligible
for this analysis. Twenty-four (27.0 %) patients were re-
ferred to the four hospitals after their initial hysterectomy.
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All hysterectomies were performed by gynecologists or
gynecological oncologists. The reasons and indications for
performing an inadvertent SH are shown in Table 1.
Fourteen patients (15.7 %) had no preoperative Pap smear.
Eleven (12.4 %) women had a normal cytology, but the Pap
smears were incompletely evaluated in 3 of these patients.
An abnormal cytology (≥ ASCUS or AGC) was identified
in 56 patients who underwent a colposcopy-directed
biopsy. Cervicitis or CIN1-2 was diagnosed in 14 cases
(15.7 %), and pre-invasive or microinvasive cervical cancer
was diagnosed in 42 cases using this procedure. An indi-
cated conization procedure was not performed in 5 (5.6 %)
cases. Thirty-seven (41.6 %) women were diagnosed with a
pre-invasive or microinvasive cervical cancer following a
conization. These patients showed positive margins in the
conization specimen and residual invasive cancer was
observed in their hysterectomy specimens. This was the
most common reason for performing inadvertent SH.
Pre-invasive or microinvasive cervical cancer was the
most common indication (47.2 %) for hysterectomies. The
remaining 47 patients were preoperatively diagnosed as
having benign disease. All of the hysterectomies were total,
including intrafascial hysterectomies which were performed
in 16 cases (18.0 %). Thirty-six patients (40.4 %) under-
went unilateral (2 cases) or bilateral (34 cases) salpingo-
oophorectomy during hysterectomy. None of the 89
patients had macroscopic disease after SH, as determined
during a review of the records for initial hysterectomies,
clinical examinations, and imaging scans, such as ultrasonic
inspections, CT or MRI, and sometimes PET-CT.
The demographic and clinicopathological characteristics
of these patients are summarized in Table 2. The mean
Table 1 Reasons, indications and surgical approaches used for inadvertent hysterectomy in patients who underwent surgery
because of a cervical cancer finding
Parameters No. %
Reasons
No preoperative Pap smear 14 15.7
Negative fractional curettage 4 4.5
Emergent operation 3 3.4
Absence of preoperative cytology and histology of the cervix 7 7.9
Negative Pap smear 11 12.4
False negative 8 9.0
Incompletely evaluated 3 3.4
Colposcopy-directed biopsy 14 15.7
Cervicitis 6 6.7
CIN1-2 8 9.0
Conization procedure 42 47.2
Pre-insive or microinvasive cervical cancer 37 41.6
Failure to perform an indicted conization 5 5.6
Data not available 8 9.0
Indications
Pre- or microinvasive cervical cancer 42 47.2
Pre-insive 26 29.2
Microinvasive 16 18.0
Benign disease 47 52.8
Leiomyoma 16 18.0
Adnexal mass 12 13.5
Adenomyosis 11 12.4






Bai et al. BMC Cancer  (2016) 16:507 Page 3 of 9
Table 2 Clinicopathological characteristics of the the included 89 patients
Parameter Number of patient Percent (%)




SCCa 75 84.3 %
ADb 12 13.5 %





Tumor width (Mean, range) 12.5 ± 9.1, (3–35)
≤20 mm 69 77.5
>20 mm 20 22.5
Stromal invasion depth (Mean, range) 5.6 ± 3.9, (2–21)
≤5 mm 66 74.2




Positive margin in hysterectomy specimens 3 3.4
Vaginal invasion 1 1.1











Follow-up (Month, range) 52.7 ± 27.2, (7–120)
Relapse 4 4.5




5-year RFSl (%) 93.9
5- year OSm (%) 94.7
Note: aSquamous cell carcinoma; bAdenocarcinoma; cAdenosquamous carcinoma; dLymph node metastasis; eLymphovascular space involvement; fRadiotherapy;
gChemoradiation therapy; hChemotherapy; iNo evidence of the disease; jAlive with the disease; kDead of the disease; lRelapse -free survival; and mOverall survival
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age at diagnosis was 45.2 years old. The most common
histology of the tumors (84.3 %) was squamous cell car-
cinoma (SCC). The average tumor width was 12.5 mm,
and the average stromal invasion depth was 5.6 mm.
Pelvic lymphadenectomy was performed in 76 cases
(85.4 %) an average of 23 days after the initial surgery
(range: 14–47 days), and 15 of these patients underwent
simultaneous para-aortic lymphadenectomy. Lymphade-
nectomy was omitted in 12 women who underwent RT
or CCRT directly. One patient refused to receive further
lymphadenectomy and indicated RT, and this patient
eventually died of the disease. Six patients underwent bi-
lateral ovarian transposition during lymphadenectomy.
The mean number of lymph nodes removed was 23.2 ±
6.0 per patient (range: 7–44). LNM was found in 6
(7.9 %) women, resulting in a total of 32 positive nodes.
The mean delay time from hysterectomy to RT, which
was performed in 36 (40.4 %) patients, was 47 (range
15–64) days. Scheduled RT was delayed in 2 (7.7 %) pa-
tients because of severe radiation enteritis. CT was per-
formed in 26 (29.2 %) cases. Forty-eight (53.9 %)
patients did not receive any adjuvant treatment.
The mean follow-up period was 52.7 months. Nine
(25 %) patients suffered late complications related to RT
that required further management. These complications
included frozen pelvis (4 cases), radiation cystitis (3
cases), intestinal obstruction (3 cases), radiation proctitis
(2 cases), and rectovaginal fistula (1 case). Two patients
with intestinal obstruction required surgical manage-
ment, and one of them developed short bowel syndrome
postoperatively. During the follow-up period, 4 (4.5 %)
patients experienced a relapse. The disease recurred lo-
cally in 1 case, at distant sites in 2 cases, and both locally
and at distant sites in 1 case (Table 3). The distant
metastasis sites included the lungs (2 cases), sternum (1
case) and left supraclavicular lymph nodes (1 case). The
mean relapse interval was 24.0 months. Three (3.4 %)
women died of multiple metastases of the disease, and
one (1.1 %) patient was living with the disease at last
contact. In total, 85 (95.5 %) women were alive without
any evidence of residual tumor at the time of their last
visit (Table 2). The 5-year RFS and 5-year OS rates were
93.9 and 94.7 %, respectively, for the entire series. A
tumor width > 20 mm, deep stromal invasion, and LNM
were identified as significant risk factors for relapse
(P < 0.001, < 0.001, and = 0.001, respectively) and sur-
vival (P = 0.003, 0.004, and 0.027, respectively; Table 4)
in the univariate analysis. No parameter was identified
as an independent risk factor for relapse or survival
in the multivariate analysis. All of the patients with a
Table 3 The characteristics of patients who developed recurrence after adjuvant therapy
Patient Age
(years)













1 ≤45 SCC 2 33 13 + - + CCRT Local 35 35 AWD
2 >45 AD 2 33 21 + - + CCRT Distant 18 43 DOD
3* >45 SCC 1 34 9 - + unknown Obs Both 9 25 DOD
4 ≤45 SCC 2 28 6 - - unknown CCRT Both 34 54 DOD
Note: *This patient refused lymphadenectomy and RT or CT
Table 4 Risk factors related to relapse and survival
Parameter Relapse P valuea DOD P valuea
+ - + -
Age
≤45 2 50 0.720 2 51 0.417
>45 2 35 1 35
Tumor width
≤20 mm 0 69 <0.001 0 69 0.003
>20 mm 4 16 3 17
Histology
SCC 3 72 0.586 2 73 0.421
AD and ASC 1 13 1 13
Grade
1 1 29 0.725 1 29 0.901
2 + 3 3 56 2 57
Stromal invasion depth
≤5 mm 0 66 <0.001 0 66 0.004
>5 mm 4 19 3 20
LVSI
+ 2 20 0.335 1 21 0.851
- 2 65 2 65
Section margin
+ 1 2 0.095 1 2 0.079
- 3 83 2 84
LNM
+ 2 4 0.001 1 5 0.027
- 0 70 0 70
Adjuvant therapy
Observation 1 47 Reference 1 47 Reference
RT 3 33 0.135 2 34 0.420
CT 3 23 0.086 2 24 0.294
Note: aLog rank test
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tumor width ≤ 20 mm and superficial stromal invasion
had a clear section margin in their hysterectomy
specimens and had no positive lymph node when
lymphadenectomy was performed. None of the pa-
tients in this group developed recurrence or died of
the disease (0/56).
Patients in the observation (Obs) subgroup had a
slightly more favorable prognosis than those who re-
ceived RT or CT (5-year PFS: 97.8 % vs 87.7 % and
83.8 %, respectively, P = 0.172; 5-year OS: 97.4 % vs
90.3 % and 87.9 %, respectively, P = 0.545). The clinico-
pathological characteristics of the Obs, RT and CT sub-
groups were compared and are shown in Table 5.
Patients with factors associated with a more favorable
prognosis, such as a tumor width ≤ 20 mm, superficial
stromal invasion, and negative LNM (P = 0.001, < 0.001,
and = 0.004, respectively) were more likely to be man-
aged using observation. In addition, RT with or without
CT was more likely to be performed in elderly women
(P = 0.002), possibly because of the adverse effect of RT
on ovarian function. In the observation subgroup, no pa-
tient (0/44) developed relapse or died of the disease
among the patients with a tumor width ≤ 20 mm and
superficial stromal invasion. In contrast, in RT or CT
subgroup, 3 of 9 patients with a tumor size > 20 mm and
deep stromal invasion developed relapse, and 2 of them
died of the disease. The 5-year RFS and 5-year OS in this
latter patient group were only 57.1 and 66.7 %, respect-
ively (P < 0.001 and = 0.008, respectively; Fig. 1-αandβ).
Thus, RT or CT can be safely omitted in patients with a
tumor width ≤ 20 mm, superficial stromal invasion, and
negative LNM.
Table 5 Comparison of clinic0-pathological characteristics of patients in the RT, CT and Obs subgroups
Parameter Obs RT CT P value
Age
≤45 34 13 10 0.002a
>45 14 23 16
Histology
SCC 42 29 22 0.384a
AD + ASC 6 7 4
Grade
1 21 9 5 0.076a
2 + 3 27 27 21
Tumor width
≤20 mm 44 20 18 0.001a
>20 mm 4 16 8
Stromal invasion depth
≤5 mm 47 15 14 <0.001a
>5 mm 1 21 12
LVSI
+ 9 12 6 0.301a
- 39 24 20
Positive margin in hysterectomy specimens
+ 1 2 2 0.396a
- 47 34 24
LNM
+ 0 6 6 0.004a
- 47 18 15
Follow-up duration (Mean, range); months 52.9 ± 29.4, (7–103) 53.0 ± 23.5, (20–120) 50.9 ± 26.0, (17–105) 0.939b
Recurrence, n (%) 1 (2.1) 3 (8.3) 3 (15.4) 0.208a
Death, n (%) 1 (2.1) 2 (5.6) 2 (11.5) 0.495a
5-year RFS (%) 97.8 87.7 83.8 0.172c
5-year OS (%) 97.4 90.3 87.9 0.545c
Note: aChi-square test or Fisher’s exact test; bKruskal-Wallis Test; cLog rank test
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Discussion
OICC is not rare, and there is no well-established opti-
mal approach for treating this disease. The best way to
manage this clinical dilemma is to prevent its occur-
rence. OICC has mainly been attributed to inadequate
preoperative workup. Its reported incidence was as high
as 12.9 % several decades ago [33, 34], but it has signifi-
cantly dropped to 2.7 % from 6.4 % in more recent stud-
ies [14, 16, 35] and was 1.9 % in the present series. This
improvement is possibly because of the development of
improved screening technologies that can better detect
cervical cancer, and an enhanced awareness in both pa-
tients and doctors about disease prevention. The vast
majority of cases are now diagnosed preoperatively.
Based on our data, no preoperative cytology, incomplete
preoperative evaluation, and a false negative Pap smear
accounted for 28.1 % of the reasons for performing an
inadvertent hysterectomy. Finding an invasive cancer in
a hysterectomy specimen after a conization procedure
with positive margins was the most common reason
(41.6 %) for performing an inadvertent SH. A positive
margin in a conization specimen suggests the presence
of residual disease in a hysterectomy specimen [36].
However, conization lacks sufficient negative predictive
value to detect pathological parameters in hysterectomy
specimens under these conditions [37, 38]. Thus, when
patients are diagnosed with pre-invasive or microinva-
sive carcinoma of the cervix after a conization and show
positive margins in the conization specimen, secondary
conization or radical hysterectomy was recommended.
The current treatments available for OICC after SH
include RP and partial vaginectomy with pelvic
lymphadenectomy, or adjuvant RT with or without
CT. None of the patients underwent RP in our series,
and we therefore have no direct experience with this
management strategy. The reported operative morbid-
ities in RP range widely, from 8.7 to 30 % [16]. The
relatively high morbidity rates were mainly attributed
to the difficulty of administering RP after SH because
of the paucity of tissue that can be removed during
the operation [15]. The success of this procedure
largely depends on the surgeon’s experience and skill
[8, 35]. The rate of serious late complications associ-
ated with RT or CCRT in our series was as high as
27 %, which was in agreement with the results de-
scribed in Park’s report [16].
Women in whom small volume (≤2 cm) tumors were
observed who also simultaneously presented with other
favorable factors were defined as low risk for parametrial
invasion and LNM and were considered to have a favor-
able prognosis [22–27]. Most of the patients with OICC
had small volume tumors, which might also have poten-
tially contributed to their misdiagnosis before SH. The
mean tumor width was 12.5 mm, and 77.5 % of the pa-
tients had a tumor width ≤ 2 cm in our series. The rates
of vaginal invasion and parametrial invasion were only
1.1 and 2.2 %, respectively. However, these data might be
underestimated to some extent, because RP and partial
vaginectomy were not performed in our series. Several
previous studies had similar results [16, 35, 39]. Thus,
this patient group might benefit from conservative treat-
ment, such as simple observation.
The reported 5-year OS in OICC patients (after RT
or CCRT) in the literature ranges from 54 to 94 %
[5–10, 16, 17, 40]. In the present work, the 5-year
RFS and 5-year OS were 87.7 and 90.3 %, respect-
ively, in the RT subgroup and 83.8 % and 87.9 %, re-
spectively, in the CT subgroup. A tumor width >
Fig. 1 A comparison of relapse (Fig. 1-α) and survival curves (Fig. 1-β) between Subgroup A and Subgroup B. None of the patients had developed relapse
or died of the disease at the last contact in patients in Subgroup A. In contrast, the 5-year RFS and 5-year OS in the patients in Subgroup B were 57.1 %
and 66.7 %, respectively (P< 0.001, P= 0.008, respectively). Note: Subgroup A: patients with a tumor width≤ 20 mm and superficial stromal invasion in the
observation subgroup (n= 44). Subgroup B: patients with a tumor size > 20 mm and deep stromal invasion in the RT or CT subgroup (n= 9)
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20 mm, deep stromal invasion, and LNM were identi-
fied as significant risk factors for relapse and survival
in the univariate analysis. The roles that these risk
factors play in predicting prognoses in patients with
early-stage cervical cancer have been demonstrated in
an accumulating number of retrospective studies that
have been published in the literature [22–28]. These
data were not validated in this study using a multi-
variate analysis, because of limitations that were asso-
ciated with the relatively small sample size of our
series. According to our data, patients with a tumor
width ≤ 20 mm and superficial stromal invasion all
had hysterectomy specimens that showed a clear sec-
tion margin in their hysterectomy specimens, and had
no LNM when lymphadenectomy was performed.
Among the patients who had these favorable prognos-
tic factors in the observation subgroup, none devel-
oped recurrence or died of the disease at the last
contact in patients who had these favorable prognos-
tic factors in the observation subgroup. In contrast,
the 5-year RFS and 5-year OS were as low as 57.1
and 66.7 % in patients with a tumor size > 20 mm
and deep stromal invasion in either the RT or the CT
subgroups. These results suggest that it may be safe
to omit RT or CT in patients with a tumor width ≤
20 mm, superficial stromal invasion, a negative sec-
tion margin, and negative LNM.
LNM was also uncommon in OICC and was found in
only 6.7 % of cases in the present study. Omitting
lymphadenectomy in early-stage cervical cancer was an-
other attractive option. Kodama et al. [41] reviewed the
literature and demonstrated that the rate of LNM was
2.0 % in patients with a tumor size < 2 cm and negative
LVSI, and this finding was also confirmed in our previ-
ous study [28]. Based on the present data, none of the pa-
tients with a tumor width ≤ 20 mm and superficial stromal
invasion had a positive lymph node when a lymphadenec-
tomy was performed. However, nodal status has been dir-
ectly correlated with patient survival [28, 42]. Performing
MRI examinations and/or biopsies to evaluate sentinel
lymph nodes both offer the potential of improving
the sensitivity of pelvic lymph node evaluations [43].
Omitting lymphadenectomy procedures could be cau-
tiously applied in patients with low-risk factors for
LNM who give fully informed consent. Otherwise,
this procedure should continue to be conserved, ei-
ther to provide prognostic information or to guide
post-operative treatment.
Despite the limitations of its retrospective nature, the
present study was conducted using a multi-center design
and relatively complete clinicopathological reports and
follow-up information. In addition, the data in this ana-
lysis spans the most recent ten years, and therefore re-
flect the latest treatment outcomes for this disease.
Conclusions
Adjuvant RT or CT could be safely omitted in patients
with OICC who also have a tumor width ≤ 20 mm,
superficial stromal invasion, no LNM and a negative sec-
tion margin in a hysterectomy specimen. However, fur-
ther studies with a larger sample population are
warranted to validate these results.
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